VÃ-ctor Javier SÃ¡nchez-ArÃ©valo Lobo

List of Publications by Year
in descending order

22 papers	1,142 citations	516710 16 h-index	677142 22 g-index
22 all docs	22 docs citations	22 times ranked	2618 citing authors

#	Article	IF	Citations
1	Targeting BPTF Sensitizes Pancreatic Ductal Adenocarcinoma to Chemotherapy by Repressing ABC-Transporters and Impairing Multidrug Resistance (MDR). Cancers, 2022, 14, 1518.	3.7	4
2	Molecular Alterations in Pancreatic Cancer: Transfer to the Clinic. International Journal of Molecular Sciences, 2021, 22, 2077.	4.1	5
3	Transcriptional regulation by NR5A2 links differentiation and inflammation in the pancreas. Nature, 2018, 554, 533-537.	27.8	101
4	c-Myc downregulation is required for preacinar to acinar maturation and pancreatic homeostasis. Gut, 2017, 67, gutjnl-2016-312306.	12.1	18
5	c-MYC partners with BPTF in human cancer. Molecular and Cellular Oncology, 2016, 3, e1152346.	0.7	23
6	Choline Kinase Alpha (CHKÎ±) as a Therapeutic Target in Pancreatic Ductal Adenocarcinoma: Expression, Predictive Value, and Sensitivity to Inhibitors. Molecular Cancer Therapeutics, 2016, 15, 323-333.	4.1	25
7	BPTF is required for c-MYC transcriptional activity and in vivo tumorigenesis. Nature Communications, 2016, 7, 10153.	12.8	104
8	Mnk1 is a novel acinar cell-specific kinase required for exocrine pancreatic secretion and response to pancreatitis in mice. Gut, 2015, 64, 937-947.	12.1	13
9	Ribonucleoprotein HNRNPA2B1 Interacts With and Regulates Oncogenic KRAS in Pancreatic Ductal Adenocarcinoma Cells. Gastroenterology, 2014, 147, 882-892.e8.	1.3	56
10	RAB7 Controls Melanoma Progression by Exploiting a Lineage-Specific Wiring of the Endolysosomal Pathway. Cancer Cell, 2014, 26, 61-76.	16.8	86
11	Dual regulation of Myc by Abl. Oncogene, 2013, 32, 5261-5271.	5.9	26
12	Sirtuin-1 Regulates Acinar-to-Ductal Metaplasia and Supports Cancer Cell Viability in Pancreatic Cancer. Cancer Research, 2013, 73, 2357-2367.	0.9	59
13	ICAT is a novel Ptf1a interactor that regulates pancreatic acinar differentiation and displays altered expression in tumours. Biochemical Journal, 2013, 451, 395-405.	3.7	6
14	The Role of the Proto-Oncogene c-myc in B Lymphocyte Differentiation. Critical Reviews in Immunology, 2012, 32, 321-334.	0.5	6
15	MYC degradation: deubiquitinating enzymes enter the dance. Nature Cell Biology, 2007, 9, 729-731.	10.3	23
16	Enhanced antiangiogenic therapy with antibody-collagen XVIII NC1 domain fusion proteins engineered to exploit matrix remodeling events. International Journal of Cancer, 2006, 119, 455-462.	5.1	30
17	Modulation of the p38 MAPK (mitogen-activated protein kinase) pathway through Bcr/Abl: implications in the cellular response to Ara-C. Biochemical Journal, 2005, 387, 231-238.	3.7	22
18	Full Activation of PKB/Akt in Response to Insulin or Ionizing Radiation Is Mediated through ATM. Journal of Biological Chemistry, 2005, 280, 4029-4036.	3.4	231

#	Article	IF	Citations
19	Adenovirus E1a protein enhances the cytotoxic effects of the herpes thymidine kinase-ganciclovir system. Cancer Gene Therapy, 2003, 10, 152-160.	4.6	10
20	Role of the p38 MAPK pathway in cisplatin-based therapy. Oncogene, 2003, 22, 3998-4006.	5.9	148
21	Regulation of p73 by c-Abl through the p38 MAP kinase pathway. Oncogene, 2002, 21, 974-979.	5.9	105
22	Modulation of PI3K/Akt pathway by E1a mediates sensitivity to cisplatin. Oncogene, 2002, 21, 7131-7136.	5.9	41